Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanoxel and Herzuma in Metastatic Salivary Duct Carcinoma
NCT03614364Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Sep 2018
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Nanoxel M and trastuzumab in salivary duct carcinoma (SDC), sponsored by Samsung Medical Center. Primary endpoint: Response rate at 24 months. Status: unknown.
02
Drugs
Nanoxel Mtrastuzumab
03
Conditions
salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on NCT03614364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614364.